Skip to main navigation Skip to search Skip to main content

Acetyl Salicylic Acid, COX-2 Inhibitors and Other NSAIDs and Breast Cancer Survival in a Finnish Population-Based Cohort

Research output: Contribution to journal › Article › Scientific › peer-review

20 Downloads (Pure)

Abstract

Background: Non-steroidal anti-inflammatory drugs (NSAIDs), particularly acetylsalicylic acid (ASA), have been associated with reduced breast cancer (BCa) mortality. While overexpression of cyclooxygenase-2 (COX-2) correlates with poorer prognosis in BCa, COX-2 inhibitors (coxibs) have not demonstrated a survival advantage. However, the evidence remains conflicting and limited. We examined associations between BCa mortality and NSAID use in a Finnish population-based cohort. Methods: The study cohort, 73 170 women with new BCa diagnosis during 1995–2013 was identified from The Finnish Cancer Registry. Follow-up data including date and the cause of death, NSAID purchases from 1995 to 2015, mammography screening participation and tumor hormone receptor status, were obtained from national registries. NSAID purchases were categorized into NSAIDs overall, ASA, and coxibs. BCa-specific and overall survival by NSAID use were analyzed using Cox proportional hazard regression, adjusted for age, tumor extent, primary treatment, Charlson comorbidity index, hypertension, diabetes, mammography participation, and hormonal therapy. Results: Pre-diagnostic use of NSAIDs (HR 0.78, 95% CI: 0.75–0.81) and coxibs (HR 0.76, 95% CI: 0.71–0.81) was associated with reduced BCa mortality, while ASA showed no association. Post-diagnostic NSAID use was associated with increased BCa mortality (HR 1.27, 95% CI: 1.22–1.33), while ASA use (HR 0.84, 95% CI: 0.73–0.97) showed dose-dependent risk reduction. Conclusion: Post-diagnostic use of ASA is associated with reduced BCa-specific mortality, distinguishing ASA from other NSAIDs. Clinical trials are required to determine the ideal ASA dose, frequency, and duration for treating BCa. Pre-diagnostic use of NSAIDs overall is associated with a slight reduction in BCa mortality without dose dependence. The potential role of pre-diagnostic NSAID use as a prognostic factor in BCa warrants further investigation.

Original languageEnglish
Article numbere70271
JournalCancer Reports
Volume8
Issue number7
DOIs
Publication statusPublished - Jul 2025
Publication typeA1 Journal article-refereed

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Publication forum classification

  • Publication forum level 1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Acetyl Salicylic Acid, COX-2 Inhibitors and Other NSAIDs and Breast Cancer Survival in a Finnish Population-Based Cohort'. Together they form a unique fingerprint.

Cite this